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doi:10.1Objective: The implantation of autologous bone marrow–derived cells has been used for the treatment of ische-
mic diseases, but obvious interindividual differences were observed in the improvement of regional perfusion and
cardiac function after treatment. We examined the angiogenic potency of bone marrow cells from patients with
different clinical backgrounds.
Methods: Bone marrow cells were collected from 25 patients scheduled to undergo sternotomy for various sur-
gical procedures. We examined the quality of bone marrow cells and investigated their angiogenic potency by
using an ischemic limb model in mice with severe combined immunodeficiency.
Results: When compared with their control cohort, bone marrow cells from patients with advanced age, renal
failure, or anemia had significantly less c-kit– and CD34-positive stem cells (P< .05) and showed significantly
lower vascular endothelial growth factor production and colony-forming units in culture (P<.05). Furthermore,
the implantation of bone marrow cells from patients with advanced age, renal failure, or anemia into the ischemic
limbs of mice also resulted in significantly worse blood flow recovery and clinical score when compared with the
implantation of bone marrow cells from their control cohorts (P< .05). However, the bone marrow cells from
patients with diabetes and hypertension did not show significant impairment of angiogenic potency when com-
pared with their control cohorts.
Conclusions: The quality and angiogenic potency of bone marrow cells differs among patients. Advanced age,
renal failure, and anemia should be the risk factors related to poor angiogenic potency of bone marrow cells for the
treatment of ischemic diseases. (J Thorac Cardiovasc Surg 2010;139:459-65)E
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SBone marrow–derived (stem) cells have been used to induce
angiogenesis for the treatment of ischemic diseases,1-4 and
the clinical application of autologous cells has no ethical or
immunologic problems. However, randomized controlled tri-
als have reported conflicting data about the beneficial effects
of using autologous bone marrow cells for the treatment of is-
chemic cardiovascular diseases.2-4 Furthermore, obvious in-
terindividual differences in the improvement of regional
perfusion and cardiac function were observed after the im-
plantation of autologous bone marrow cells.1-4 A subgroup
analysis of the REPAIR–AMI study revealed that a good out-
come was observed in patients with large infarct size and poor
left ventricular function.4 Conversely, the BOOST study sug-
gested that the outcomes of bone marrow cell implantation
were not related to the patient’s age, left ventricular function,e Department of Surgery and Clinical Science, Yamaguchi University Gradu-
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The Journal of Thoracic and Caor time to cell delivery.2 However, we do not exactly know
the factor that influences the outcome of therapy.
The mechanism of the induction of therapeutic angiogenesis
by bone marrow cells is extremely complex, involving the
quality of the cells used for implantation and the condition of
the targeted ischemic tissue.5,6 Many factors, such as aging, di-
abetes, and other systemic diseases have been found to contrib-
ute to the functional impairment of bone marrow cells.7-10 This
might explain poor outcomes in some patients after autologous
bone marrow cell implantation for the treatment of ischemic
heart diseases.1-4 Therefore it is critically important to identify
the risk factors that contribute to the functional impairment of
bone marrow cells for inducing therapeutic angiogenesis.
In this study we collected bone marrow cells from patients
with different clinical backgrounds. We examined the qual-
ity of bone marrow cells by means of in vitro assessments and
also investigated their angiogenic potency using an ischemic
limb model in mice with severe combined immunodefi-
ciency (SCID mice). We found that advanced age, renal fail-
ure, and anemia were the risk factors that contributed to poor
angiogenic potency of the bone marrow cells of patients.
MATERIALS AND METHODS
Collection of BoneMarrow Cells From Patients With
Different Clinical Backgrounds
Twenty-five patients (age range, approximately 44–84 years; mean age,
65.110.7 years) were enrolled in this study. The diagnoses of theserdiovascular Surgery c Volume 139, Number 2 459
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S46Abbreviations and Acronyms0SCID mice ¼ mThe Jourice with severe combined
immunodeficiencyVEGF ¼ vascular endothelial growth factorpatients were ischemic heart disease in 10 patients, valve disease in 12 pa-
tients, thymoma in 2 patients, and patent ductus arteriosus in 1 patient. All
patients underwent a scheduled operation performed through a sternotomy.
The ethics review board at our university approved this study, and written
informed consent was obtained preoperatively from every patient.
About 15 mL of bone marrow fluid was aspirated from the sternum be-
fore sternotomy for surgical procedure. Bone marrow mononuclear cells
were isolated by means of density gradient centrifugation. An average of
1.35 (1.351.12)3108 bone marrow mononuclear cells were collected
from 1 patient, and freshly isolated cells were used immediately for exper-
iments.
Characterization of Bone Marrow Cells
The expression of CD34 and c-kit in freshly isolated bone marrow cells
was measured by means of flow cytometry, as described previously.11
Briefly, cells were incubated for 30 minutes at 4 C with fluorescein isothio-
cyanate–conjugated mouse anti-human CD34 antibody and phycoerythrin-
conjugated mouse anti-human c-kit antibody (Miltenyi Biotec, Bergisch
Gladbach, Germany). Quantitative flow cytometric analysis was done
with a FACS SCAN flow cytometer and Cell Quest software (Becton
Dickinson, Franklin Lakes, NJ).
Evaluation of the Potency of Vascular Endothelial
Growth Factor Production and Colony Formation of
Bone Marrow Cells
Vascular endothelial growth factor (VEGF) production and colony for-
mation from bone marrow cells was evaluated as described previously.8
Briefly, freshly isolated bone marrow mononuclear cells from each patient
were suspended in RPMI 1640 medium supplemented with 10% fetal bo-
vine serum (Gibco BRL, Carlsbad, Calif) and cultured at 37 C in a humid-
ified environment with 5% CO2. After 3 days of culture on 96-well plates,
supernatant was collected, and the concentration of VEGF in the superna-
tant was measured with ELISA kits (R&D Systems, Minneapolis, Minn).
Colony-forming assay was done by culturing cells on a BIOCOAT CELL-
WARE 24-well plate (Becton Dickson Labware, Bedford, Mass), and the
number of colony-forming units was counted after 10 days of cultivation.8
Ischemic Hind-Limb Model of Mice and the
Implantation of Patient’s Bone Marrow Cells
We investigated the angiogenic potency of the patient’s bone marrow
cells in vivo by using an acute ischemic hind-limb model in SCID
mice.12 Briefly, an ischemic hind-limb model was created in 12- to 15-
week-old mice. After the initiation of limb ischemia, bone marrow mononu-
clear cells from patients were injected intramuscularly, with a total of 13106
cells at 4 points (each with 2.53105 cells/10 mL of saline) in the ischemic
hind limbs of mice. Cells from 1 patient were injected into 4 to 6 mice to
reduce the individual differences.
Measurement of Blood Flow and Clinical Score
Blood flow in the ischemic hind limb was measured by using a laser
Doppler perfusion imaging system (PeriScan PIM II; Lisca AB, Linkoping,
Sweden) 28 days after treatment, as described previously.12 The recovery of
perfusion in the ischemic hind limb of each mouse was estimated by the per-
centage of limb blood flow, which was calculated by the average perfusionnal of Thoracic and Cardiovascular Surgin the left hind limb compared with that in the normal right hind limb. We
also recorded the clinical scores of the ischemic hind limbs in all mice 28
days after treatment, as described previously.13 The mean blood flow and
mean clinical scores of 4 to 6 mice represented the data of 1 patient and
were used for statistical analysis.
Statistical Analysis
Data are expressed as means  SDs. Statistical significance between 2
groups was determined by using the 2-tailed unpaired t test.
RESULTS
Interindividual Differences of Angiogenic Potency of
Bone Marrow Cells From Patients
The bone marrow cells from different patients achieved
different degrees of improvement in regional blood flow
and the clinical score of the ischemic hind limbs of mice
28 days after cell implantation (Figure 1). Blood flow recov-
ery and the clinical score of the ischemic limbs were better in
mice receiving bone marrow cells from younger patients, but
poor blood flow and clinical scores of ischemic limbs were
observed in mice receiving bone marrow cells from older pa-
tients. The mean values of blood flow and clinical score of 4
to 6 mice receiving bone marrow cells from each patient
were used for statistical analysis.
Advanced Age Contributes to the Impairment of
Angiogenic Potency of Bone Marrow Cells
Compared with the young patients (<65 years), bone mar-
row cells from patients with advanced age (65 years) con-
sisted of significantly less c-kit– and CD34-positive cells
(P< .01; Figure 2, A). In culture, bone marrow cells from
patients with advanced age produced less VEGF and formed
fewer colonies than those from younger patients (P< .01;
Figure 2, B). The blood flow and clinical scores were signif-
icantly worse in the ischemic limbs of mice that received
bone marrow cells from patients with advanced age (65
years) than those from younger patients (<65 years;
P< .01; Figure 2, C). Furthermore, the age of patients sig-
nificantly and linearly correlated with both the blood flow
(r ¼ 0.565, P ¼ .003) and clinical scores (r ¼ 0.432,
P ¼ .03) in the ischemic limbs of mice receiving bone
marrow cells from the patients.
Anemia Is a Risk Factor for Poor Angiogenic Potency
of Bone Marrow Cells
Compared with patients with normal hemoglobin values
(12 g/dL), bone marrow cells from patients with anemia
(hemoglobin,<12 g/dL) had significantly less c-kit– and
CD34-positive stem cells (P< .01; Figure 3, A). In vitro
analysis showed that bone marrow cells from patients with
anemia produced less VEGF and formed fewer colonies
(P< .05; Figure 3, B). The blood flow and clinical scores
were significantly worse in the ischemic limbs of mice that
received the implantation of bone marrow cells from patients
with anemia than from those with normal hemoglobin valuesery c February 2010
FIGURE 1. In vivo assessment of the angiogenic potency of bone marrow cells from patients using an ischemic limb model in SCID mice. Representative
images show the improved appearance (top) and blood flow (below) in ischemic limbs of mice 28 days after the implantation of bone marrow cells from 2
patients. The clinical scores and blood flow were obviously worse in the mice implanted with bone marrow cells from the elderly patients (left) than in those
implanted with bone marrow cells from the younger patients (right). Data are expressed as the means SDs of 4 mice injected with bone marrow cells from 1
patient.
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levels of patients significantly and linearly correlated with
the blood flow (r ¼ 0.522, P ¼ .007) and clinical scores
(r¼0.438, P¼ .03) in the ischemic limbs of mice receiving
bone marrow cells from the patients.
Poor Angiogenic Potency of Bone Marrow Cells
From Patients With Renal Failure
We found that bone marrow cells from patients with renal
failure (dialysis) also had significantly less c-kit– and CD34-
positive stem cells than those from patients without renal
failure (P< .05; Figure 4, A). Although the production of
VEGF by bone marrow cells did not differ between the 2
groups, the number of colony-forming units seen on cultur-
ing bone marrow cells from patients with renal failure were
significantly less than those from patients without renal fail-
ure (P< .05; Figure 4, B). Furthermore, the blood flow and
clinical scores were also significantly worse in the ischemic
limbs of mice that received bone marrow cells from patients
with renal failure than those from patients without renal fail-
ure (P< .05; Figure 4, C).
Diabetes and Hypertension Did Not Contribute to
Decreased Angiogenic Potency of Bone Marrow Cells
Unexpectedly, the data from our in vitro experiments
showed that the number of c-kit– and CD34-positive stem
cells in bone marrow did not decrease significantly in pa-
tients with diabetes (all are insulin independent; Figures 5,
A, and 6, A) when compared with numbers seen in their con-
trol cohorts. The in vitro production of VEGF by bone mar-
row cells also did not differ significantly between diabetic
and nondiabetic patients, although the formation of colonies
tended to decrease in the diabetic patients (P¼ .07; Figure 5,
B). No difference in the in vitro production of VEGF and
colony formation from bone marrow cells was observedThe Journal of Thoracic and Cabetween patients with hypertension and patients without
hypertension (Figure 6, B). In vivo studies also showed
that the blood flow and clinical scores were not different
in the ischemic limbs of mice that received bone marrow
cells from patients with diabetes and hypertension when
compared with their control cohorts (Figures 5, C, and 6, C).DISCUSSION
In this study we examined the quality and angiogenic po-
tency of bone marrow cells from 25 patients with different
backgrounds. We found that bone marrow cells from differ-
ent patients had a different proportion of c-kit– and CD34-
positive stem cells, different degrees of VEGF production
and colony formation in vitro, and different potency to im-
prove the blood flow and clinical scores of ischemic limbs
in mice after implantation. Furthermore, the angiogenic po-
tency of bone marrow cells from patients was closely related
to the number of c-kit– and CD34-positive stem cells in their
bone marrow (data not shown). These data support that the
angiogenic potency of bone marrow cells has obvious inter-
individual differences among patients.
We found that bone marrow cells from patients with ad-
vanced age had poor improvement in blood flow to the ische-
mic limbs of mice. Experimental studies have found that bone
marrow cells from young but not old mice incorporated into
the neovasculature and restored cardiac angiogenic func-
tions.10,14 A reduced number of granulocyte–macrophage
colony-forming units of the bone marrow cells from patients
with advance age has also been reported.15 Our study has fur-
ther demonstrated in vivo the age-related impairment of an-
giogenic potency of bone marrow cells from patients with
advanced age. The molecular mechanisms for age-related
functional impairment of bone marrow cells could be very
complex, including cell senescence, enhanced oxidative
stress, and others.16-18 It has been found that aging isrdiovascular Surgery c Volume 139, Number 2 461
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FIGURE 2. Comparison of the angiogenic potency of bone marrow cells
from the elderly and young patients. A, The bone marrow cells from patients
of advanced age had significantly lower numbers of c-kit–positive (left) and
CD34-positive (right) stem cells than those from younger patients. B, The
concentration of vascular endothelial growth factor (VEGF) in the condi-
tioned medium (left) and the number of colony-forming units (right) were
significantly lower after 3 or 7 days of cultivation of bone marrow cells
from the elderly patients than those from the young patients. C, The blood
flow (left) and clinical scores (right) in the ischemic limbs of mice were sig-
nificantly worse 28 days after implantation with bone marrow cells from the
elderly patients than those from the young patients. Each circle represents
the mean value of blood flow and clinical score of 4 to 6 mice injected
with bone marrow cells of 1 patient.
A
B
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FIGURE 3. Angiogenic potency of bone marrow cells from patients with
or without anemia. A, The bone marrow cells from patients with anemia (he-
moglobin [Hb],<12 g/dL) had significantly lower numbers of c-kit–positive
(left) and CD34-positive (right) stem cells than those from patients without
anemia. B, The concentration of vascular endothelial growth factor (VEGF)
in the conditioned medium (left) and the number of colony-forming units
(right) were significantly lower after 3 or 7 days of cultivation of bone mar-
row cells from patients with anemia than from those without anemia. C, The
blood flow (left) and clinical scores (right) in the ischemic limbs of mice were
significantly worse 28 days after the implantation with bone marrow cells
from patients with anemia than from those without. Each circle represents
the mean value of blood flow and clinical scores of 4 to 6 mice injected
with bone marrow cells of 1 patient.
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row cells, and the reduction of telomere length was associated
with a reduced ex vivo migratory response.17 This indicates
that age-associated telomere reduction might contribute to
functional impairment of bone marrow cells. However, the
precise mechanisms of age-related functional impairment
in bone marrow cells were not completely understood, and
we did not investigate the relative mechanisms in this study.462 The Journal of Thoracic and Cardiovascular SurgWe have also found that bone marrow cells from patients
with renal failure had a deceased angiogenic potency in vivo,
although a previous study has demonstrated impaired migra-
tory activity and adhesion of endothelial progenitor cells in
patients receiving long-term hemodialysis.19 Interestingly,
a low hemoglobin level in the patients was found to relate
significantly to the poor angiogenic potency of their bone
marrow cells. Because these patients had no signs of acuteery c February 2010
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FIGURE 4. Angiogenic potency of bone marrow cells from patients with
or without renal failure (RF). A, The bone marrow cells from patients with
renal failure (dialysis) had significantly lower numbers of c-kit–positive
(left) and CD34-positive (right) stem cells than those from their control co-
horts. B, The number of colony-forming units (right) were significantly
lower after 7 days of cultivation of bone marrow cells from the patients
with renal failure than from those without, but the concentration of vascular
endothelial growth factor (VEGF) in the conditioned medium (left) after 3
days of cultivation did not differ between groups. C, The blood flow (left)
and clinical scores (right) in the ischemic limbs of mice were significantly
worse 28 days after the implantation with bone marrow cells from patients
with renal failure than from those without. Each circle represents the mean
value of blood flow and clinical scores of 4 to 6 mice injected with bone
marrow cells of 1 patient.
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FIGURE 5. Comparison of the angiogenic potency of bone marrow cells
from diabetic patients and their control cohorts. A, The numbers of c-kit–
positive (left) and CD34-positive (right) stem cells in bone marrow did
not differ between diabetic patients and their control cohorts. B, The con-
centration of vascular endothelial growth factor (VEGF) in the conditioned
medium (left) and the number of colony-forming units (right) were also not
significantly different after 3 and 7 days of cultivation of bone marrow cells
from diabetic patients and their control cohorts, although the number of col-
ony-forming units tended to decrease in bone marrow cells from the diabetic
patients. C, Bone marrow cells from diabetic and nondiabetic patients
showed similar improvement of blood flow (left) and clinical scores (right)
28 days after implantation into the ischemic limbs of mice. Each circle rep-
resents the mean value of blood flow and clinical scores of 4 to 6 mice in-
jected with bone marrow cells of 1 patient. DM, Diabetes mellitus.
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Sor chronic blood loss, a low hemoglobin level implicates im-
paired hematopoietic function, which means a poor quality
of bone marrow stem cells. Although anemia was very often
observed in patients undergoing dialysis, comparable hemo-
globin levels were observed between patients with and with-
out renal failure (11.2 1.7 vs 11.8 1.9 g/dL, P¼ .975) in
our study. Therefore we considered that both renal failureThe Journal of Thoracic and Caand anemia are the risk factors related to poor angiogenic po-
tency of bone marrow cells.
In contrast to previous investigations,7-9,18,20,21 we found
that diabetes, hypertension, ischemic heart disease, and
smoking (data not shown) were not risk factors for poor an-
giogenic potency of the bone marrow cells. These discrep-
ancies might be attributed to the different cell sources andrdiovascular Surgery c Volume 139, Number 2 463
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FIGURE 6. Comparison of the angiogenic potency of bone marrow cells
from patients with or without hypertension (HT). A, The numbers of c-
kit–positive (left) and CD34-positive (right) stem cells in bone marrow
did not differ between patients with and without hypertension. B, The con-
centration of vascular endothelial growth factor (VEGF) in the conditioned
medium (left) and the number of colony-forming units (right) were also not
significantly different after 3 and 7 days of cultivation of bone marrow cells
from diabetic patients and their control cohorts, although the number of col-
ony-forming units tended to decrease in bone marrow cells from the diabetic
patients. C, Bone marrow cells from diabetic and nondiabetic patients
showed similar improvement of blood flow (left) and clinical scores (right)
28 days after implantation into the ischemic limbs of mice. Each circle rep-
resents the mean value of blood flow and clinical scores of 4 to 6 mice in-
jected with bone marrow cells of 1 patient.
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Sexperimental methods used among studies. The previous
studies have used young healthy volunteers for the control
group,21 but the control cohort in this study was composed
of age-matched patients. Because advanced age was identi-
fied as one of the important risk factors contributing to func-
tional impairment of bone marrow cells, it is not surprising464 The Journal of Thoracic and Cardiovascular Surgthat a worse function of bone marrow cells was found in
these patients with ischemic heart disease (average age, 60
years) when compared with young healthy volunteers (aver-
age, 30 years) in the previous study.21
This study has several limitations. First, we examined the
quality of bone marrow cells by culturing cells under nor-
moxic conditions and estimated the angiogenic potency of
the patients’ bone marrow cells using an ischemic limb
model of SCID mice. However, the ischemic tissue was spe-
cialized as a hypoxic microenviroment, and culturing cells
under normoxic condition might not correctly reflect the po-
tential functional difference of cells after implantation into
the ischemic tissue. Otherwise, many other systemic and lo-
cal angiogenic factors, including endothelial function, cyto-
kines, and growth factors, differ among patients, and it
would be impossible to reproduce these differences in our is-
chemic limb model in mice.
Second, the small sample size of this study might prevent
us from detecting some potential risk factors (eg, diabetes)
that have been demonstrated to contribute to the functional
impairment of bone marrow cells.
Third, the small sample size of the study limited us to mul-
tivariate analysis. It is well know that renal failure, anemia,
and old age are commonly associated in the same clinical
process. Although the hemoglobin level is not different ei-
ther between the aged and young patients or between the pa-
tients with and without renal failure, the independence of
these risk factors need to be identified by means of further
study of a large sample size with multivariate analysis.
Finally, we obtained bone marrow cells for study from
about 15 mL of sternal marrow after anesthetic induction.
However, many clinical trials collected cells by means of il-
iac aspiration of more (50–500 mL) bone marrow for im-
plantation. The different methods might collect bone
marrow cells with a different cell subpopulation and result
in different angiogenic potency.
Although further studies with a large population size are
required to identify and confirm our data, it is a well-ac-
cepted fact that functional impairment of autologous bone
marrow cells can be induced by some systemic and regional
disorders, and the implantation of autologous bone marrow
cells in these patients might contribute to poor angiogenic
potency. Because previous studies have found that the im-
plantation of ‘‘young’’ cells into the aged mice induces ef-
fective angiogenesis,10,14 allografting of bone marrow cells
from healthy donors could be an option for these patients
with functional impairment of their bone marrow cells. Re-
cent study has observed that allografting of mesenchymal
stem cells into ischemic heart has functional benefit in sheep
without an obvious immunologic problem.22 However, the
immunologic and safety problems of allografting bone mar-
row mononuclear cells remain to be clarified because of the
contamination of some lymphocytes in bone marrow mono-
nuclear cells. Because the therapeutic potency of boneery c February 2010
Li et al Evolving Technology/Basic Sciencemarrow–derived cells could be enhanced by gene modifica-
tion,23 hypoxic preconditioning,24 and pretreatment with
some drugs,18 autologous bone marrow cells will be avail-
able for use in these patients if we can restore the impaired
function of cells ex vivo before implantation.
In summary, we demonstrated that the quality and angio-
genic potency of bone marrow cells obviously differs among
patients with different clinical backgrounds. We identified
that advanced age, renal failure, and anemia are risk factors
related to poor angiogenic potency of bone marrow cells for
the treatment of ischemic diseases.E
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